1. Home
  2. PHAR vs RGR Comparison

PHAR vs RGR Comparison

Compare PHAR & RGR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Pharming Group N.V.

PHAR

Pharming Group N.V.

HOLD

Current Price

$18.21

Market Cap

1.1B

Sector

Health Care

ML Signal

HOLD

Logo Sturm Ruger & Company Inc.

RGR

Sturm Ruger & Company Inc.

HOLD

Current Price

$32.30

Market Cap

521.9M

Sector

Industrials

ML Signal

HOLD

Company Overview

Basic Information
Metric
PHAR
RGR
Founded
1988
1949
Country
Netherlands
United States
Employees
N/A
N/A
Industry
Biotechnology: Pharmaceutical Preparations
Ordnance And Accessories
Sector
Health Care
Industrials
Exchange
Nasdaq
Nasdaq
Market Cap
1.1B
521.9M
IPO Year
N/A
N/A

Fundamental Metrics

Financial Performance
Metric
PHAR
RGR
Price
$18.21
$32.30
Analyst Decision
Strong Buy
Analyst Count
2
0
Target Price
$38.00
N/A
AVG Volume (30 Days)
24.0K
463.7K
Earning Date
11-06-2025
11-05-2025
Dividend Yield
N/A
2.15%
EPS Growth
N/A
N/A
EPS
0.00
0.16
Revenue
$362,274,000.00
$540,770,000.00
Revenue This Year
$25.19
$0.73
Revenue Next Year
$4.47
$2.27
P/E Ratio
$3,041.40
$205.50
Revenue Growth
26.78
3.90
52 Week Low
$7.50
$28.33
52 Week High
$18.12
$48.21

Technical Indicators

Market Signals
Indicator
PHAR
RGR
Relative Strength Index (RSI) 58.10 46.71
Support Level $16.98 $30.93
Resistance Level $17.00 $33.01
Average True Range (ATR) 0.69 1.09
MACD 0.03 0.31
Stochastic Oscillator 82.04 45.36

Price Performance

Historical Comparison
PHAR
RGR

About PHAR Pharming Group N.V.

Pharming Group is a biopharmaceutical company focused in transforming the lives of patients with rare, debilitating, and life-threatening diseases. The company is actively developing and commercializing a diverse portfolio of innovative treatments, including both biologics and small molecule therapies. Its commercial products are RUCONEST, approved for the treatment of acute attacks in adult and adolescent patients with hereditary angioedema, or HAE; and Joenja (leniolisib), a small-molecule kinase inhibitor, developed for the treatment of activated phosphoinositide 3-kinase delta syndrome.

About RGR Sturm Ruger & Company Inc.

Sturm Ruger & Co Inc and its subsidiary are principally engaged in the design, manufacture, and sale of firearms to domestic customers. The company's design and manufacturing operations are in the United States and almost all product content is domestic. The company has two reportable operating segments: firearms and castings. The firearms segment manufactures and sells rifles, pistols, and revolvers principally to a number of federally-licensed, independent wholesale distributors located in the United States. The castings segment manufactures and sells steel investment castings and metal injection molding parts. It generates maximum income from the sale of Firearms.

Share on Social Networks: